ENTOD Pharma eyes skyrocket sales of Macushield tabs in 2022

07 April 2022 | News

Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improve overall vision

Image Credit: Shutterstock

Image Credit: Shutterstock

ENTOD Pharmaceuticals is eyeing sales of more than half a million strips of Macushield tablets in 2022. Macushield tablets were developed by the research team of ENTOD Pharmaceuticals in early 2012, and since then have been available in both Indian and overseas markets.


"The product has seen exponential growth over the years both in the domestic and overseas international markets. We expect the sale of Macushield to skyrocket in 2022 owing to a growing awareness of eye health and preventable blindness in the public,” said Nikkhil K Masurkar, Executive Director, ENTOD Pharmaceuticals.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account